Developer docs
API playgroundTry for free, no card

Search company profiles

LBBW VC

Full company profile

uuid002vcao

Namestring
LBBW VC
Legal namestring
LBBW Venture Capital GmbH
Websiteurl
lbbwvc.de
Company typeenum
Private
Founded yearint
1998
Descriptiontext

LBBW Venture Capital GmbH (LBBW VC) is a Stuttgart-based corporate venture capital firm and wholly-owned subsidiary of Landesbank Baden-Württemberg, founded in 1998. The firm invests in early-stage (Seed to Series A) disruptive IT and life science companies across the DACH region, deploying initial ticket sizes of up to €3 million. Its stated focus areas are Digital Transformation (Enterprise IT, IoT, Industry 4.0, AI/ML, Big Data & Analytics across mobility, manufacturing, energy and cleantech), Life Science and HealthTech (drug development, diagnostics, MedTech, Healthcare IT), and Financial Technology. The firm differentiates itself through the patient-capital posture enabled by its state-bank parent, granting an investment horizon longer than typical 10-year fund vehicles.

The firm's go-to-market is direct: founders submit pitch decks via email ([email protected]) or LinkedIn, after which the in-house investment team screens and leads or co-invests. Recent disclosed activity includes a €51M Series B in Exciva (Alzheimer's therapy, Jan 2026), an €11M seed in Oska Health (AI chronic care, Feb 2026), a €10M Series A in metergrid (tenant energy platform, Jan 2026), and repeated follow-on capital in metergrid. LBBW VC does not develop technology products itself; its "product" is capital plus non-financial support, including market access, sector expertise, and privileged access to one of Germany's largest real estate portfolios for relevant portfolio companies.

The 9-person team includes Managing Directors with prior exits including two unicorns (SolarEdge and View) and Senior Investment Managers drawn from corporate VC arms of Bosch, ams Osram and HELLA/Forvia. Revenue and AUM are not publicly disclosed, and the firm's economic model functions as an internal CVC vehicle for LBBW rather than a third-party fund manager.

Short descriptiontext

LBBW VC is the Stuttgart-based corporate venture capital arm of Landesbank Baden-Württemberg, investing Seed-to-Series-A capital (up to €3m) in disruptive IT and life science startups across the DACH region, backed by the parent bank's long-term investment horizon.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStuttgart, Germany
HQ citystring
Stuttgart
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, early-stage equity financing, digital transformation investments, life science venture capital, DACH region startups
Industry1 code
1Early-Stage Venture Capital (Series A/B)
CodeFSANAAABPrimaryYes
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns and Capital Gains
TypeSubscription Recurring
Description

As a venture capital firm, LBBW VC generates returns through equity investments in early-stage companies, with proceeds realized through exits via IPOs, acquisitions, or secondary transactions.

lbbwvc.de
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

LBBW VC provides early-stage equity financing (Seed to Series A) with initial ticket sizes of up to €3 million to disruptive IT and life science companies in the DACH region. As an independent subsidiary of Landesbank Baden-Württemberg, the firm leverages the parent bank's long-term capital perspective to support portfolio companies in Digital Transformation, Life Science & HealthTech, and Financial Technology sectors, complemented by industry expertise and access to LBBW's network including one of Germany's largest real estate portfolios.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

LBBW VC is a venture capital firm and does not offer a product or service in the traditional sense. It operates as an investment company that provides early-stage financing (Seed to Series A) to disruptive IT and life science companies in the DACH region. The company's investment focus areas include Digital Transformation (Enterprise IT, IoT, Industry 4.0, AI/ML, Big Data & Analytics), Life Science and HealthTech (drug development, diagnostics, MedTech, Healthcare IT), and Financial Technology. Their service offering consists of capital investment and growth support for portfolio companies, not a software product or platform.

Product and service4 records
1Early-Stage Equity Financing
CategoryVenture Capital Financing
2Digital Transformation Investments
CategoryVenture Capital - Digital/SaaS
3Life Science and HealthTech Investments
CategoryVenture Capital - Life Sciences
4Financial Technology Investments
CategoryVenture Capital - FinTech
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment47 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LBBW VC

Venture Capitallbbwvc.de

LBBW VC is the Stuttgart-based corporate venture capital arm of Landesbank Baden-Württemberg, investing Seed-to-Series-A capital (up to €3m) in disruptive IT and life science startups across the DACH region, backed by the parent bank's long-term investment horizon.

What LBBW VC does

LBBW Venture Capital GmbH (LBBW VC) is a Stuttgart-based corporate venture capital firm and wholly-owned subsidiary of Landesbank Baden-Württemberg, founded in 1998. The firm invests in early-stage (Seed to Series A) disruptive IT and life science companies across the DACH region, deploying initial ticket sizes of up to €3 million. Its stated focus areas are Digital Transformation (Enterprise IT, IoT, Industry 4.0, AI/ML, Big Data & Analytics across mobility, manufacturing, energy and cleantech), Life Science and HealthTech (drug development, diagnostics, MedTech, Healthcare IT), and Financial Technology. The firm differentiates itself through the patient-capital posture enabled by its state-bank parent, granting an investment horizon longer than typical 10-year fund vehicles.

The firm's go-to-market is direct: founders submit pitch decks via email ([email protected]) or LinkedIn, after which the in-house investment team screens and leads or co-invests. Recent disclosed activity includes a €51M Series B in Exciva (Alzheimer's therapy, Jan 2026), an €11M seed in Oska Health (AI chronic care, Feb 2026), a €10M Series A in metergrid (tenant energy platform, Jan 2026), and repeated follow-on capital in metergrid. LBBW VC does not develop technology products itself; its "product" is capital plus non-financial support, including market access, sector expertise, and privileged access to one of Germany's largest real estate portfolios for relevant portfolio companies.

The 9-person team includes Managing Directors with prior exits including two unicorns (SolarEdge and View) and Senior Investment Managers drawn from corporate VC arms of Bosch, ams Osram and HELLA/Forvia. Revenue and AUM are not publicly disclosed, and the firm's economic model functions as an internal CVC vehicle for LBBW rather than a third-party fund manager.

LBBW VC firmographics

Firmographics
Name
LBBW VC
Legal name
LBBW Venture Capital GmbH
Website
https://lbbwvc.de
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
1–10 employees
Short description
LBBW VC is the Stuttgart-based corporate venture capital arm of Landesbank Baden-Württemberg, investing Seed-to-Series-A capital (up to €3m) in disruptive IT and life science startups across the DACH region, backed by the parent bank's long-term investment horizon.
Ownership category
akta.pro rank

LBBW VC industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (52394), Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro primary industry
Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

  • Venture capital investing
  • Early-stage equity financing
  • Digital transformation investments
  • Life science venture capital
  • DACH region startups

Where LBBW VC is headquartered

Location

Headquarters

HQ city
Stuttgart
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

LBBW VC business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Investment Returns and Capital Gains: As a venture capital firm, LBBW VC generates returns through equity investments in early-stage companies, with proceeds realized through exits via IPOs, acquisitions, or secondary transactions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

LBBW VC product offering

Product offering

Core offering

LBBW VC provides early-stage equity financing (Seed to Series A) with initial ticket sizes of up to €3 million to disruptive IT and life science companies in the DACH region. As an independent subsidiary of Landesbank Baden-Württemberg, the firm leverages the parent bank's long-term capital perspective to support portfolio companies in Digital Transformation, Life Science & HealthTech, and Financial Technology sectors, complemented by industry expertise and access to LBBW's network including one of Germany's largest real estate portfolios.

Product overview

LBBW VC is a venture capital firm and does not offer a product or service in the traditional sense. It operates as an investment company that provides early-stage financing (Seed to Series A) to disruptive IT and life science companies in the DACH region. The company's investment focus areas include Digital Transformation (Enterprise IT, IoT, Industry 4.0, AI/ML, Big Data & Analytics), Life Science and HealthTech (drug development, diagnostics, MedTech, Healthcare IT), and Financial Technology. Their service offering consists of capital investment and growth support for portfolio companies, not a software product or platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early-Stage Equity Financing
  • Digital Transformation Investments
  • Life Science and HealthTech Investments
  • Financial Technology Investments

Companies that use LBBW VC

Customer profile

Segments3 records

Ideal customer profiles3 records

LBBW VC technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LBBW VC partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

LBBW VC competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

LBBW VC social profiles

Digital presence

LBBW VC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LBBW VC leadership team

Management profile

Number of profiles

Profiles9 records

LBBW VC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LBBW VC M&A and investment

M&A and investment

M&A

Investments47 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LBBW VC

What does LBBW VC do?

LBBW VC provides early-stage equity financing (Seed to Series A) with initial ticket sizes of up to €3 million to disruptive IT and life science companies in the DACH region. As an independent subsidiary of Landesbank Baden-Württemberg, the firm leverages the parent bank's long-term capital perspective to support portfolio companies in Digital Transformation, Life Science & HealthTech, and Financial Technology sectors, complemented by industry expertise and access to LBBW's network including one of Germany's largest real estate portfolios.

Is LBBW VC a public or private company?

LBBW VC is a private company. It is classified as corporate owned and is currently operating.

When was LBBW VC founded?

LBBW VC was founded in 1998. It employs 1 to 10 people.

Where is LBBW VC based?

LBBW VC is headquartered in Stuttgart, Germany, in the Europe region.

How does LBBW VC make money?

One revenue line is on record: investment Returns and Capital Gains.

Does LBBW VC have an API?

No public API is recorded for LBBW VC.

What industry is LBBW VC in?

LBBW VC's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CoinMarketCapRL1 launches with 10 European finance firms: Guest Post by crypto.newsRegulated Layer One (RL1), a Luxembourg-based European Cooperative Society, launched on July 28 with 10 financial institutions as founding members, including ABN AMRO, Cecabank, Crédit Mutuel Alliance Fédérale, DekaBank, DZ BANK, LBBW, Natixis CIB, SC Ventures, and Seturion. The network, led by former SWIAT managing director Henning Vollbehr, is built on SWIAT's production infrastructure, which processed over 50 transactions worth more than €700 million before the transfer of ownership. NatWest is expected to formally join in the coming weeks, while KfW plans an autumn test using its third blockchain bond on the RL1/SWIAT network.GlobeNewswireleon-nanodrugs secures funds in a series D financing to broaden portfolio in first single-use high throughput production systems for nanoencapsulationleon-nanodrugs GmbH closed a Series D financing round with LBBW Venture Capital as lead investor. The funds will augment its product portfolio of single-use high-throughput nanoencapsulation systems for cell and gene therapy manufacturing. The company plans to use the capital to select a strategic partner for commercialization.Leon-Nanodrugsleon-nanodrugs secures funds in a series D financingLEON announced the closing of a Series D financing round, with LBBW Venture Capital serving as the lead investor alongside new and existing shareholders. LEON is a pharmatech company specializing in nanoparticle encapsulation equipment for pharmaceutical and biotech applications.Yahooleon-nanodrugs secures funds in a series D financing to broaden portfolio in first single-use high throughput production systems for nanoencapsulationleon-nanodrugs GmbH closed a Series D financing round led by LBBW Venture Capital, with participation from existing investors including Albany Private Equity Holdings and TVM Life Science Innovation I L.P. The company intends to use the new funds to broaden its portfolio of single-use high throughput production systems for nanoencapsulation in the Cell & Gene Therapy industry. This investment supports LEON's goal to advance its manufacturing solutions toward commercialization and strategic partnership.WebdisclosureLeon-nanodrugs Secures Series D Financing for Nanoencapsulation Production SystemsLeon-nanodrugs GmbH closed a Series D financing round on August 6, 2024, with participation from LBBW Venture Capital and existing shareholders like Albany Private Equity Holdings Pty Ltd. The capital will enhance LEON's nanoencapsulation systems aimed at the Cell & Gene Therapy industry, focusing on efficient manufacturing solutions for individualized therapies.GlobeNewswireleon-nanodrugs secures funds in a series D financing to broaden portfolio in first single-use high throughput production systems for nanoencapsulationleon-nanodrugs GmbH closed a Series D financing round led by LBBW Venture Capital, with participation from existing investors such as Albany Private Equity Holdings and TVM Life Science Innovation I L.P. The company intends to use the funds to broaden its portfolio of single-use high throughput production systems for nanoencapsulation, specifically targeting the Cell & Gene Therapy industry. This investment supports LEON's strategy to bring its proprietary FR-JET® reactor technology products to market and facilitate commercial manufacturing.FinSMEsExciva Raises €9M in Series A FundingExciva GmbH, a clinical biotech company based in Heidelberg, Germany, closed a €9 million Series A financing round led by Andera Partners with participation from LBBW Venture Capital and Cure8. The company plans to utilize the funds to advance its lead compound, Deraphan®, through Phase I development for treating agitation and aggression in Alzheimer’s disease patients.PR NewswireTeralytics lève 17,5 millions de dollars pour améliorer la mobilité des personnes dans le mondeTeralytics AG, a Zurich-based mobility technology company, announced the closing of a $17.5 million funding round led by Robert Bosch Venture Capital GmbH, with participation from Deutsche Bahn Digital Ventures, innogy Ventures, LBBW Venture Capital, Liil Ventures, and existing investors Atomico and Lakestar. The company, which develops data-driven mobility solutions using telecommunications network data to help cities and transport services understand and improve human movement patterns, plans to expand its coverage to over one billion trips and establish itself as a global marketplace for mobility advisory services. Teralytics operates from Zurich with additional offices in New York and Singapore.PR NewswireTeralytics Raises $17.5 Million to Improve Human Mobility WorldwideTeralytics AG announced it has raised $17.5 million in a funding round led by Robert Bosch Venture Capital GmbH, with participation from Deutsche Bahn Digital Ventures, innogy Ventures, LBBW Venture Capital, Liil Ventures, and existing investors Atomico and Lakestar. The Zurich-based company, which provides mobility insights solutions using telecom network data, plans to use the funding to expand its coverage to over a billion journeys and establish a global marketplace for mobility insights. The investment follows a period of commercial traction and expansion into more than 10 countries, with offices in New York and Singapore.FinSMEsAcousia Therapeutics Raises Close to €10M in Series B FundingAcousia Therapeutics raised close to €10M in Series B funding from LBBW Ventures, Bregua, Boehringer Ingelheim, KfW, and Creathor. The investment will advance small-molecule drug candidates, including ACOU085 for otoprotection against cisplatin-related hearing loss.